IDI2 Inhibitors
Inhibitors of IDI2 function through a variety of biochemical mechanisms to impede the enzyme's role in critical cellular processes, particularly in the biosynthesis of sterols and isoprenoids. These inhibitors exert their effects by modulating upstream enzymes and substrates that are essential for IDI2's activity. For example, certain compounds are known to antagonize calmodulin, disrupting its interactions and subsequently influencing pathways that could govern IDI2's activity in lipid synthesis. Others are more direct in their approach, targeting the HMG-CoA reductase pathway to deplete the pool of isoprenoids, thus indirectly restraining IDI2's function. This reduction in substrate availability is a strategic means of dampening the enzyme's activity without necessitating direct binding or interaction with IDI2 itself.
The second tier of IDI2 inhibitors includes molecules that perturb lipid metabolism through activation of peroxisome proliferator-activated receptors or by acting as cofactors in enzymatic reactions that alter the balance of metabolic pathways linked to IDI2. Additionally, some inhibitors in the list target enzymes like squalene epoxidase and squalene synthase, whose inhibition could result in a diminished need for IDI2's role in cholesterol synthesis. Others disrupt cellular ionic homeostasis, which could affect IDI2's optimal functioning environment.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5′-Deoxy-5′-methylthioadenosine | 2457-80-9 | sc-202427 | 50 mg | $120.00 | 1 | |
Interferes with the methionine salvage pathway, which is indirectly related to sterol and isoprenoid biosynthesis. As IDI2 is part of this biosynthetic pathway, its activity may be reduced due to substrate depletion. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, which is upstream of the mevalonate pathway where IDI2 functions. This leads to reduced substrate availability for IDI2 and subsequent inhibition of its activity. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase, decreasing the metabolic flux through the mevalonate pathway and thereby decreasing IDI2 activity. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin, a HMG-CoA reductase inhibitor, would lead to a reduction in mevalonate pathway intermediates, which could indirectly inhibit IDI2 by reducing its substrate availability. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), which can lead to reduced expression of enzymes in the lipid synthesis pathways, decreasing IDI2 activity indirectly. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib inhibits farnesyltransferase and could reduce the demand for isoprenoid intermediates, indirectly leading to decreased functional activity of IDI2. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Ritonavir is known to inhibit cytochrome P450 enzymes, which could reduce the synthesis of certain isoprenoids, leading to reduced functional activity of IDI2. | ||||||
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
By inhibiting farnesyl diphosphate synthase, this compound affects the mevalonate pathway and could lead to an indirect inhibition of IDI2 through altered regulatory feedback within the pathway. | ||||||